Between July and November 2001 , 40 patients with HRPC and increasing prostate-specific antigen ( PSA ) or progression in measurable disease who had not received prior chemotherapy were randomly assigned to 250 mg ( n = 19 ) or 500 mg ( n = 21 ) oral gefitinib daily continuously .
